PT-141 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PT-141 is being researched for libido applications. Activates melanocortin receptors MC1R and MC4R, with MC4R modulating sexual desire through hypothalamic neural circuits. Engages endogenous melanocortin pathways regulating arousal, desire, and sexual. Common dosages for this use range from 1.75 mg per dose (FDA-approved) on-demand, 45 minutes before anticipated activity; maximum 8 doses per month.
Can PT-141 Help With Libido?
PT-141 (Bremelanotide) is being researched for libido applications based on its mechanism as a Melanocortin receptor agonist.
Activates melanocortin receptors MC1R and MC4R, with MC4R modulating sexual desire through hypothalamic neural circuits. Engages endogenous melanocortin pathways regulating arousal, desire, and sexual response — a completely different mechanism than PDE5 inhibitors like sildenafil.
What Does the Research Show for PT-141 and Libido?
FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile.
The relevance to libido specifically comes from PT-141's effects on increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What Protocol Is Used for Libido?
For libido applications, the standard PT-141 protocol is 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection for on-demand acute dosing; no continuous cycle required.
Some researchers adjust dosing based on the specific libido application — see our PT-141 dosage guide for full protocol details.
Can Stacking Improve Libido Results?
Works through a unique mechanism distinct from PDE5 inhibitors; not typically combined with other sexual enhancement agents.
What Side Effects Apply to Libido Use?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Side effects are generally consistent regardless of the specific application. See our PT-141 side effects guide for details.
Calculate Your PT-141 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PT-141.
Open Calculator →Bottom Line: PT-141 for Libido
PT-141 shows preliminary research potential for libido. Standard protocols (1.75 mg per dose (FDA-approved), on-demand, 45 minutes before anticipated activity; maximum 8 doses per month, on-demand acute dosing; no continuous cycle required) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
PT-141 (Bremelanotide): Research
Related Reading
- PT-141 Dosage Guide
- PT-141 Benefits
- PT-141 Side Effects
- PT-141 Stacking Guide
- PT-141 Cycle Guide
- PT-141 Research
Research-Grade Sourcing
If you're going to research PT-141, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What is the recommended PT-141 dosage?
Common dosages: 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection. Cycle length: on-demand acute dosing; no continuous cycle required. Half-life: peak effects 15-30 minutes post-injection. Use our peptide calculator for exact reconstitution math.
What are the side effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Is PT-141 safe?
PT-141 has shown a preliminary safety profile in research. FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. All research should follow appropriate safety protocols.